Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04013971 · ClinicalTrials.gov registry record · NA
Innovative Biofeedback Interface for Enhancing Stroke Gait Rehabilitation
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT04013971: Completed NA study, sponsored by Emory University.
NCT04013971 is a NA study that has completed, run by Emory University. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04013971, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study will conduct a preliminary evaluation of and obtain user data on a novel game-based visual interface for stroke gait training. Study participants will complete one session comprising exposure to gait biofeedback systems in an order determined by randomization. Participants will be exposed to 2 types of biofeedback interfaces: * newly developed game-based interface (projector screen display) * traditional, non-game interface
Primary Outcome
Paretic leg (right leg for post-stroke participants) or targeted leg (right leg for able-bodied participants) peak push off force (peak AGRF) was calculated from GRF data. Higher values indicate greater push off force.
Interventions
- OTHER Control Condition
- OTHER AGRF Biofeedback Game
- OTHER Traditional Biofeedback Interface
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2023-03-31 |
| Phase | NA |
What the finished NCT04013971 record still lists
NCT04013971 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Control Condition is the first listed.
NCT04013971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04013971 about?
NCT04013971 is a clinical study titled "Innovative Biofeedback Interface for Enhancing Stroke Gait Rehabilitation". This study will conduct a preliminary evaluation of and obtain user data on a novel game-based visual interface for stroke gait training. Study participants will complete one session comprising exposure to gait biofeedback systems in an order determined by randomization. Participants will be exposed...
What is the current status of trial NCT04013971?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2022-04-04. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT04013971?
The interventions under investigation include: Control Condition (OTHER), AGRF Biofeedback Game (OTHER), Traditional Biofeedback Interface (OTHER).
Who is sponsoring clinical trial NCT04013971?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04013971's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI